#1 Clinical Trials Search in Europe

Nadunolimab

Nadunolimab, also known as CAN04, is an innovative drug currently being studied in clinical trials for the treatment of various types of cancer. This fully humanized monoclonal antibody targets IL1RAP (Interleukin 1 Receptor Accessory Protein) and is being tested in combination with standard chemotherapy regimens. The trials aim to evaluate its safety, efficacy, and potential benefits for patients with advanced solid tumors, including triple-negative breast cancer, colorectal cancer, non-small cell lung cancer, and biliary tract cancer.

Table of Contents

What is NADUNOLIMAB?

NADUNOLIMAB, also known as CAN04, is a new type of cancer treatment currently being studied in clinical trials[3]. It is a fully humanized monoclonal antibody, which means it’s a laboratory-made protein that acts like the antibodies naturally produced by our immune system. This drug is designed to target a specific protein in the body called IL1RAP (Interleukin 1 Receptor Accessory Protein)[2].

How Does NADUNOLIMAB Work?

NADUNOLIMAB works in two main ways to fight cancer:

  1. It blocks signals within cancer cells that are produced by the IL1RAP protein. This impairs the cancer cells’ ability to release substances that stimulate tumor growth, potentially reducing inflammation and slowing down tumor progression[2].
  2. It activates the immune system to fight cancer cells. By attaching to the IL1RAP protein on cancer cells, NADUNOLIMAB helps the body’s immune system recognize and attack these harmful cells[2].

What Cancers Does NADUNOLIMAB Treat?

NADUNOLIMAB is being studied for its potential to treat several types of cancer, including:

  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[1].
  • Acute Myelogenous Leukemia (AML): A type of blood and bone marrow cancer[1].
  • Triple Negative Breast Cancer (TNBC): An aggressive form of breast cancer that doesn’t respond to hormonal therapies or treatments targeting HER2 protein[2].
  • Colorectal Cancer: Cancer that starts in the colon or rectum[3].
  • Non-Small Cell Lung Cancer (NSCLC): The most common type of lung cancer[3].
  • Biliary Tract Cancer: Cancer that occurs in the bile ducts[3].

Clinical Trials and Research

NADUNOLIMAB is currently being studied in several clinical trials:

  • A Phase 1B/2A trial is testing NADUNOLIMAB in combination with other drugs (azacitidine and venetoclax) for patients with MDS and AML[1].
  • The TRIFOUR study is a Phase 1b/2 trial investigating NADUNOLIMAB combined with chemotherapy (gemcitabine and carboplatin) in patients with advanced triple negative breast cancer[2].
  • A Phase 1/2 study is examining NADUNOLIMAB in combination with different chemotherapy regimens for various advanced solid tumors[3].

These trials aim to determine the safety, proper dosage, and effectiveness of NADUNOLIMAB in treating different types of cancer.

Potential Side Effects

As NADUNOLIMAB is still in clinical trials, the full range of potential side effects is not yet known. However, researchers are closely monitoring patients for any adverse reactions. Common side effects observed with cancer treatments may include fatigue, nausea, and changes in blood cell counts. The clinical trials are designed to assess the safety and tolerability of NADUNOLIMAB when used alone or in combination with other treatments[2][3].

Future Prospects

While NADUNOLIMAB is still in the research phase, early results are promising. If successful, this drug could provide a new treatment option for patients with various types of cancer, especially those who have not responded well to existing therapies. The ability of NADUNOLIMAB to potentially enhance the effectiveness of chemotherapy and activate the immune system against cancer cells makes it an exciting area of research in oncology[2][3].

As research continues, more information will become available about the effectiveness and safety of NADUNOLIMAB. Patients interested in this treatment should discuss with their healthcare providers about the possibility of participating in clinical trials or the potential future availability of this drug.

Aspect Details
Drug Name Nadunolimab (CAN04)
Drug Type Fully humanized monoclonal antibody targeting IL1RAP
Cancer Types Studied Triple-negative breast cancer, Colorectal cancer, Non-small cell lung cancer, Biliary tract cancer, Myelodysplastic syndrome, Acute myelogenous leukemia
Administration Intravenous (IV) in combination with chemotherapy
Primary Objectives Assess safety, determine recommended Phase 2 dose, evaluate efficacy
Secondary Objectives Measure tumor response, progression-free survival, overall survival, quality of life
Key Outcome Measures Adverse events, Overall Response Rate, Duration of Response, Biomarker changes
Trial Phases Phase 1/2 and Phase 1b/2a

FAQ

  • What is Nadunolimab and how does it work? Nadunolimab (CAN04) is a fully humanized monoclonal antibody that targets IL1RAP (Interleukin 1 Receptor Accessory Protein). It works by blocking signals within cancer cells, impairing their ability to secrete tumor-stimulating substances. This action helps reduce tumor growth, inflammation, and progression while also activating the immune system to fight cancer cells.
  • What types of cancer are being studied with Nadunolimab? Nadunolimab is being studied in clinical trials for various types of cancer, including triple-negative breast cancer, colorectal cancer, non-small cell lung cancer, biliary tract cancer, myelodysplastic syndrome (MDS), and acute myelogenous leukemia (AML).
  • How is Nadunolimab administered in clinical trials? Nadunolimab is typically administered intravenously (IV) in combination with standard chemotherapy regimens. The dosing schedule varies depending on the specific trial and cancer type being studied, but it is usually given on specific days within treatment cycles lasting 2-4 weeks.
  • What are the main goals of the Nadunolimab clinical trials? The main goals of the Nadunolimab clinical trials are to assess its safety and tolerability when combined with chemotherapy, determine the recommended Phase 2 dose (RP2D), evaluate its efficacy in terms of tumor response and survival outcomes, and study its effects on various biomarkers and quality of life measures.
  • Are there any known side effects of Nadunolimab? As with any investigational drug, the full side effect profile of Nadunolimab is still being studied. The clinical trials are designed to monitor and assess the frequency, duration, and severity of adverse events. Common side effects associated with cancer treatments, such as fatigue, nausea, and changes in blood cell counts, may occur. Patients in the trials are closely monitored for any potential side effects.

Ongoing Clinical Trials on Nadunolimab

  • Study of Nadunolimab with Gemcitabine and Carboplatin for Patients with Advanced Triple Negative Breast Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Monoclonal antibodies are used to treat some types of cancer.
  • IL1RAP (Interleukin 1 Receptor Accessory Protein): A protein involved in the immune system's response to inflammation. It is found at higher levels in some types of cancer cells and is the target of Nadunolimab.
  • Triple-negative breast cancer (TNBC): A type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein. It is typically more aggressive and has fewer treatment options than other types of breast cancer.
  • Chemotherapy: A type of cancer treatment that uses drugs to destroy cancer cells. It is often used in combination with other treatments, such as targeted therapies like Nadunolimab.
  • Clinical trial: A research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Dose-limiting toxicity (DLT): Side effects of a drug or treatment that are serious enough to prevent an increase in dose or level of that treatment.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug determined in early-phase clinical trials to be appropriate for further testing in larger, later-phase trials.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment for a disease that patients are still alive.
  • Quality of Life (QoL): The standard of health, comfort, and happiness experienced by an individual or group, often measured in clinical trials to assess the impact of treatments on patients' well-being.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Anti-drug antibodies (ADA): Antibodies produced by the immune system against a therapeutic drug, which can potentially reduce its effectiveness or cause side effects.

References